Alvotech (ALVOW)

NasdaqGM: ALVOW · 실시간 가격 · USD

0.22

+0.02 (10.00%)

종가 기준: Aug 25, 2026, 4:06 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

10.00% (1D)

데이터 없음

매수호가	1.24
시가총액	n/a
매출 (ttm)	494.61M
순이익 (ttm)	-179.59M
	0.18
	n/a
	n/a
	n/a
P/B (ttm)	-0.54
P/S (ttm)	n/a
실적 발표일	n/a

매도호가	1.3
거래량	1,807
평균 거래량 (20일)
시가	1.52
전일 종가	0.20
일중 범위	0.22 - 0.23
52주 범위	0.22 - 0.23
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

ALVOW 소개

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing s...

[더 보기]

산업

섹터

IPO 일자 Jul 17, 2026

직원 수 1,279

상장 거래소 NasdaqGM

티커 ALVOW

웹사이트 https://www.alvotech.com

전체 기업 정보

재무 실적

2025년 Alvotech의 매출은 586.32M로, 전년 489.68M 대비 19.74% 증가했습니다. 순이익은 27.92M로, -112.04% 감소했습니다.

재무제표

뉴스

1주 전 · MarketBeat

Alvotech Q2 Earnings Call Highlights

Alvotech (NASDAQ:ALVO) said its first-half 2026 results reflected a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site, while management reaffirmed...

1주 전 · Moby

Alvotech Q2 2026 Earnings Call Summary

Moby summary of Alvotech's Q2 2026 earnings call

1주 전 · Zacks

Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates

Alvotech (ALVO) delivered earnings and revenue surprises of -83.33% and +6.72%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1개월 전 · Simply Wall St.

Alvotech (ALVO) Stock May Be Undervalued Following Its $125 Million Offering

Alvotech stock is coming off a difficult stretch, with the share price down about 64% over the past five years, yet the broader valuation checks currently lean toward the shares looking cheap on sever...

1개월 전 · Simply Wall St.

Alvotech’s US$240 Million Capital Boost Might Change The Case For Investing In Alvotech (ALVO)

Alvotech recently amended its credit agreement to add a new US$75 million term loan facility led by GoldenTree Asset Management, following a US$165 million equity raise in June 2026, giving the compan...

2 페이지 중 1

Alvotech (ALVOW)

ALVOW 소개

재무 실적

어닝 서프라이즈

주가가 움직인 이유